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The heat shock response plays an important
role in TDP-43 clearance: evidence for
dysfunction in amyotrophic lateral sclerosis
Han-Jou Chen,1 Jacqueline C. Mitchell,1 Sergey Novoselov,2 Jack Miller,1
Agnes L. Nishimura,1 Emma L. Scotter,3 Caroline A. Vance,1 Michael E. Cheetham2 and
Christopher E. Shaw1
Detergent-resistant, ubiquitinated and hyperphosphorylated Tar DNA binding protein 43 (TDP-43, encoded by TARDBP) neur-
onal cytoplasmic inclusions are the pathological hallmark in 95% of amyotrophic lateral sclerosis and 60% of frontotemporal
lobar degeneration cases. We sought to explore the role for the heat shock response in the clearance of insoluble TDP-43 in a
cellular model of disease and to validate our ﬁndings in transgenic mice and human amyotrophic lateral sclerosis tissues. The heat
shock response is a stress-responsive protective mechanism regulated by the transcription factor heat shock factor 1 (HSF1), which
increases the expression of chaperones that refold damaged misfolded proteins or facilitate their degradation. Here we show that
manipulation of the heat shock response by expression of dominant active HSF1 results in a dramatic reduction of insoluble and
hyperphosphorylated TDP-43 that enhances cell survival, whereas expression of dominant negative HSF1 leads to enhanced TDP-
43 aggregation and hyperphosphorylation. To determine which chaperones were mediating TDP-43 clearance we over-expressed a
range of heat shock proteins (HSPs) and identiﬁed DNAJB2a (encoded by DNAJB2, and also known as HSJ1a) as a potent anti-
aggregation chaperone for TDP-43. DNAJB2a has a J domain, allowing it to interact with HSP70, and ubiquitin interacting
motifs, which enable it to engage the degradation of its client proteins. Using functionally deleted DNAJB2a constructs we
demonstrated that TDP-43 clearance was J domain-dependent and was not affected by ubiquitin interacting motif deletion or
proteasome inhibition. This indicates that TDP-43 is maintained in a soluble state by DNAJB2a, leaving the total levels of TDP-43
unchanged. Additionally, we have demonstrated that the levels of HSF1 and heat shock proteins are signiﬁcantly reduced in
affected neuronal tissues from a TDP-43 transgenic mouse model of amyotrophic lateral sclerosis and patients with sporadic
amyotrophic lateral sclerosis. This implies that the HSF1-mediated DNAJB2a/HSP70 heat shock response pathway is compromised
in amyotrophic lateral sclerosis. Defective refolding of TDP-43 is predicted to aggravate the TDP-43 proteinopathy. The ﬁnding
that the pathological accumulation of insoluble TDP-43 can be reduced by the activation of HSF1/HSP pathways presents an
exciting opportunity for the development of novel therapeutics.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neuron degenerative disease, character-
ized by progressive motor neuron loss from the spinal cord,
brainstem and motor cortex, leading to muscle weakness
and eventual respiratory failure. The average age of disease
onset is 55 years and affected individuals typically die
within 3 to 5 years of diagnosis. No effective treatments
are available and consequently there is a high unmet need
for novel therapeutic development (for review see Goyal
and Mozaffar, 2014). Approximately 10% of ALS cases
are familial, with the remaining 90% being sporadic (spor-
adic ALS). Regardless of the cause, 95% of patients share
a common molecular pathology, which involves the accu-
mulation of ubiquitinated, hyperphosphorylated and insol-
uble TDP-43 protein aggregates in the cytoplasm, and
decreased levels of TDP-43 in the nucleus (Neumann
et al., 2006; Mackenzie et al., 2007; Tan et al., 2007;
Geser et al., 2008; Brettschneider et al., 2013).
TDP-43 is a DNA and RNA binding protein that plays a
key role in regulating RNA transcription, editing, transport
and translation. It is a predominantly nuclear protein
whose levels are tightly controlled through a system of
auto-regulation (Ayala et al., 2011; Polymenidou et al.,
2011). Knockout of TDP-43 is lethal in embryonic mice,
indicating that it plays a vital role in development and sur-
vival (Kraemer et al., 2010). Although TDP-43 is predom-
inantly a nuclear protein, it is known to shuttle between the
nucleus and cytoplasm and has been identiﬁed as a com-
ponent of stress granules, which form in response to cellu-
lar stress (Belly et al., 2005; Rutherford et al., 2008;
Colombrita et al., 2009; Dion et al., 2009; Nonaka et al.,
2009). Multiple ALS-causing mutations have been identi-
ﬁed on the TARDBP gene coding for TDP-43, which pro-
motes TDP-43 translocation to the cytosol, stabilizes and
promotes the aggregation of the mutant protein (Johnson et
al., 2009; Barmada et al., 2010; Ling et al., 2010). TDP-43
is aggregation-prone and the accumulation of mutant pro-
tein in the cytoplasm correlates with toxicity (Barmada et
al., 2010; Bilican et al., 2012). In addition, overexpression
of wild-type TDP-43 in mammalian cells or transgenic
animal models leads to TDP-43 accumulation, cytotoxicity
and motor deﬁcits (Ash et al., 2010; Barmada et al., 2010;
Stallings et al., 2010; Wils et al., 2010). As TDP-43 cyto-
plasmic aggregates are observed in 95% of ALS and
tau-negative frontotemporal lobar degeneration cases, dys-
regulation of TDP-43 protein levels are a common feature
of disease pathogenesis. The targeted clearance of aggre-
gated TDP-43 is therefore a key strategy for therapeutic
intervention.
A balance of protein synthesis, folding and degradation is
needed to maintain protein homeostasis (proteostasis) and
this process is facilitated by molecular chaperones. When
cells are acutely stressed by insults that affect proteostasis,
such as heat shock, they induce a transcriptional programme
orchestrated by the transcription factor heat shock factor 1
(HSF1) to upregulate selected chaperones, known as heat
shock proteins (HSPs), to protect them from being over-
whelmed by the accumulation of aberrant proteins. HSPs
are categorized into several families according to their func-
tion and size (for review see Stetler et al., 2010). HSP90 and
HSP70 are families of classic abundant chaperones that are
expressed ubiquitously in most subcellular organelles. They
execute their chaperone function by facilitating the folding
of client proteins in an ATP-dependent manner. The human
DnaJ (HSP40) family contains 50 proteins that act as co-
chaperones for HSP70 to promote the client–chaperone
interaction by stimulating HSP70 ATP hydrolysis, producing
a high afﬁnity binding state for client protein refolding.
Some members of the HSP40 family have HSP70-independ-
ent functions and can facilitate client proteins folding on
their own or directly targeting them for degradation
(Kampinga and Craig, 2010).
Aberrant protein aggregation is a pathological hallmark
of almost all neurodegenerative diseases and the beneﬁcial
effect of increasing individual HSP expression has been
demonstrated for several neurodegenerative disease
models. For example, overexpression of the co-chaperones,
DNAJB6b and DNAJB8, suppressed the aggregation and
toxicity of poly-Q proteins (Hageman et al., 2010); over-
expression of the small HSP, HSPB8, promoted autophagic
removal of mutant SOD1 (Crippa et al., 2010); overexpres-
sion of HSP70 inhibited -synuclein ﬁbril formation
(Dedmon et al., 2005); overexpression of HSPB1 in
mutant SOD1 transgenic mice improved neuronal survival
in the early but not late stages of disease development
(Sharp et al., 2008); and overexpression of DNAJB2a in
SOD1 transgenic mice reduced SOD1 aggregation
(Novoselov et al., 2013).
In this study, we explored the potential of HSPs to clear
pathological TDP-43 aggregates and whether these chaper-
ones might be deﬁcient in animal models of TDP-43 pro-
teinopathy and patients with ALS. We established a cellular
model that recapitulated key features of the human TDP-43
proteinopathies and demonstrated that overexpression of
dominant active HSF1, or the co-chaperone DNAJB2a, dra-
matically cleared insoluble TDP-43 aggregates and im-
proved cell survival without altering levels of soluble
TDP-43. We demonstrated that DNAJB2a mediates patho-
logical TDP-43 clearance through a ubiquitin proteasome
system (UPS)-independent, HSP70-dependent mechanism.
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This suggests that the HSF1-DNAJB2a pathway refolds
TDP-43 and returns it to its natural physiological state
rather than facilitating its degradation. We also demon-
strated that the levels of HSF1 and HSPs are markedly
reduced in both a transgenic TDP-43 mouse model and
in spinal cord tissues from sporadic ALS patients. These
results highlight the potential of HSF1 and HSP activation
as an important therapeutic strategy for the TDP-43
proteinopathies.
Materials and methods
Plasmids and antibodies
The green ﬂuorescent protein (GFP)-TDP-43 constructs were
generated and used in a previous study (Nishimura et al.,
2010). HSF1( + ) and HSF1() (Fig. 1A) were generated by
altering the HSF1 constructs kindly provided by Professor
Richard Voellmy (Xia et al., 1999). They were cloned with a
V5 tag fused to the N-terminus into the pcDNA5/FRT/TO
expression vector (Life Technologies). V5-chaperone constructs
were kindly provided by Professor Harm Kampinga (Hageman
and Kampinga, 2009) and Myc-DNAJB2a constructs were
generated and used in previous studies (Chapple and
Cheetham, 2003; Westhoff et al., 2005). All plasmid sequences
were veriﬁed by DNA sequencing.
Primary antibodies used in this study included: rabbit anti-
ubiquitin, K48-speciﬁc (1:2000, Millipore); mouse anti-phos-
pho TDP-43 (1:3000, Cosmo Bio); rabbit anti-mouse TDP-
43 (0.1 mg/ml, a gift from Professor Virginia Lee; Igaz et al.,
2011); mouse anti-Myc (9B11; 1:1000 for immunoblotting,
1:100 for immunopuriﬁcation, Cell Signaling); rabbit anti-
HSP40 (C64B4; 1:1000, Cell Signaling); rabbit anti-HSP70
(1:1000, Cell Signaling); rabbit anti-HSF1 (1:1000, Cell
Signaling); mouse anti-Actin (1:4000, Sigma); rabbit anti-V5
(1:2000 for immunoblotting, 1:1000 for immunopuriﬁcation,
Sigma); mouse anti-GFP (1:1000, Santa Cruz); rabbit anti-
TDP-43 (1:2000, ProteinTech); and rabbit anti-p62 (1:10000,
Abcam). Secondary antibodies included DyLight 680 goat anti-
rabbit IgG (1:10000, Thermo Scientiﬁc); DyLight 800 goat
anti-mouse IgG (1:10000, Thermo Scientiﬁc); HRP-linked anti-
rabbit IgG (1:2000, Cell Signaling); and DyLight 488/550/650
anti-rabbit or mouse IgG (1:500, Thermo Scientiﬁc).
Cell culture and DNA transfection
HEK293T and SH-SY5Y cells were cultured using Dulbecco’s
modiﬁed Eagle medium (DMEM) and DMEM/F12 (Life
Technologies) supplemented with 10% foetal bovine serum
(Life Technologies), and maintained at 37C, 5% CO2. Cells
were plated a day before transfection and media were refreshed
before plasmid DNA transfection using Lipofectamine 2000
(Life Technologies). Cells were left for 48h after transfection
to be harvested for analysis unless otherwise stated.
Animals
All experiments were performed under the terms of the UK
Animals (Scientiﬁc Procedures) Act 1986, and were approved
by the Kings College, London ethics review panel. Compound
transgenic mice were generated by crossing TDP-43WT and
TDP-43Q331K mice as previously described (Mitchell et al.,
2015).
Mouse and human spinal cord lysate
preparation
Whole spinal cords from 8-week-old TDP-43WTxQ331K animals
and their single and non-transgenic littermates (n = 3–4) or
50mg of spinal cord post-mortem tissues from controls or
patients with sporadic ALS were homogenized in the appro-
priate amount of RIPA buffer (50mM Tris pH8.0, 150mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate with protease and phosphatase inhibitor),
sonicated and stored at80 C. Protein concentration was
determined with DCTM Protein Assay Kit (Bio-Rad). Western
blotting was run with 10 mg of protein lysate.
Immunohistochemistry
Eight-week-old, end-stage TDP-43WTxQ331K mice and age-
matched littermates were anaesthetized and transcardially
perfused with phosphate-buffered saline (PBS) followed by
4% paraformaldehyde (PFA) in phosphate buffer. Spinal
cord was postﬁxed in 4% PFA in 15% sucrose for 5 h, cryo-
protected in 30% sucrose for 24 h and cut into 30 mm
sections on a cryostat. Sections were incubated in rabbit
anti-HSF1 antibody (1:250; Cell Signaling), washed and
incubated with a biotinylated anti-rabbit antibody (1:1000;
Vector) and then incubated in an ABC kit (Vector). Sections
were imaged using a Zeiss light microscope and Axiovision
software.
Immunopurification
Cells were harvested in immunopuriﬁcation buffer (50mM
Tris pH7.4, 150mM NaCl, 1% TritonTM X-100 with protease
and phosphatase inhibitor). After centrifuging (14 000 rpm for
30 s at 4C), the supernatant was collected and incubated with
immunopuriﬁcation antibody and Dynabead protein A (Life
Technologies) overnight at 4C. The Dynabead protein A-
antibody-protein complex was puriﬁed using magnetic separ-
ation and washed with immunopuriﬁcation buffer before
eluted in loading buffer.
Solubility fractionation
The fractionation for protein solubility was performed using a
protocol described by Winton et al. (2008) with some minor
modiﬁcations. Cells were harvested in RIPA buffer, sonicated
and centrifuged at 12 000g for 20min at 4 C. After centrifu-
gation, the supernatant was collected as the RIPA solubility
fraction. The pellet, after being washed once with RIPA
buffer, was then suspended in 20% of the original lysis
volume with urea buffer (7 M Urea, 2 M Thiourea, 4%
CHAPS and 30mM Tris pH8.5) and collected as the insoluble,
detergent-resistant fraction.
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Figure 1 Expression of HSF1( + ) reduces levels of insoluble TDP-43. (A) Protein structure of human HSF1 protein and the HSF1
variants used in this study. (B) HEK293T cells co-express GFP-TDP-43 and V5-HSF1 constructs for 48 h followed by fractionation. Levels of
endogenous HSP40 and HSP70 are shown as indicators of HSR activation. Levels of GFP-TDP-43 from three independent transfections are
quantified, normalized to actin and shown in relation to GFP-WT-TDP-43 and the vector only control. Mean and SEM are shown for insoluble
fraction (C), and soluble fraction (D). Two-way ANOVA analysis indicates the difference in TDP-43 solubility is not contributed by TDP-43
genotypes or interaction between TDP-43 and HSF1, but by HSF1 alone (P5 0.001). Both HSF1( + ) and HSF1() cause significant changes in the
level of insoluble TDP-43 when co-transfected with GFP-TDP-43 when compared to the vector only control (P5 0.001, Bonferroni post-test).
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Western blotting and densitometry
analysis
Protein quantiﬁcation and western blotting were performed as
described before (Nishimura et al., 2010). Five micrograms of
cell lysate from the RIPA fraction and the equivalent liquid
volume from the urea fraction were loaded. Western blot
quantiﬁcation was performed using the image analysis soft-
ware, ImageJ (http://imagej.nih.gov/ij/). Integrated band inten-
sities were normalized to that of loading control or the RIPA
fraction.
Immunofluorescence
Cells for immunoﬂuorescent analyses were ﬁxed in 4% PFA
(VWR) for 20min and washed with PBS three times for 5min.
Cells were permeablized by incubation in PBS containing 0.5%
TritonTM X-100 (Sigma) for 15min at room temperature, fol-
lowed by blocking in PBS containing 1% donkey serum for 1 h
at room temperature. Cells were incubated with primary anti-
body diluted in blocking solution overnight at 4C. After
washing in PBS, cells were subsequently incubated with ﬂuor-
escent secondary antibodies diluted in blocking solution for 1 h
at room temperature. DAPI (Sigma) was then used to stain for
nuclei before being mounted on coverslips using FluroSave
(Calbiochem).
Cell survival assay
For cell survival assay, SH-SY5Y cells were trypsinized and
stained with Calcein Violet 450 AM Viability Dye (500 nM,
eBioscience) for 30min at room temperature. After washing
twice with PBS, cells were resuspended in PBS and analysed
with the BD FACSCanto II (BD Biosciences).
Results
Co-expression of HSF1( + ) reduces
levels of insoluble TDP-43 protein
This study used dominant active and negative forms of
HSF1 to investigate the effect of the HSR and HSP upre-
gulation on TDP-43 proteinopathy in cellular models.
HSF1 is a transcription factor that upregulates HSPs
during the stress response. In the unstressed condition,
HSF1 is bound to HSP90 via its regulatory domain and
is kept in an inactive form. During cellular stress, HSF1
dissociates from HSP90, trimerizes, translocates into the
nucleus, and binds to the heat shock element (HSE)
through its DNA binding domain (DBD), where it pro-
motes the transcription of downstream genes via its trans-
active domain (TAD) (Voellmy, 2005; Velichko et al.,
2013). To activate the HSR we used a dominant positive
HSF1, HSF1( + ), in which the regulatory domain is deleted
(Fig. 1A). This modiﬁed HSF1 is therefore unable to be
inactivated by HSP90 binding. Conversely, for comparison,
we used a dominant negative construct, HSF1(), with the
TAD domain deleted (Fig. 1A). Although this HSF1() can
still form trimers with endogenous wild-type HSF1 during
stress, it is incapable of inducing the transcription of its
targeted genes. The expression of HSF1( + ) increased the
levels of endogenous HSP40 (DNAJB1) and HSP70
(HSPA1A), demonstrating HSF1( + ) activated the HSR as
expected (Fig. 1B). On the other hand, levels of HSP40 and
HSP70 were unchanged, or slightly decreased in HSF1()
expressing cells, indicating HSF1() overexpression did not
induce the HSR, and furthermore, may even inhibit basal
HSR activation by dominant negative inhibition of en-
dogenous HSF1.
The expression level of endogenous TDP-43 in our cells
was not high enough to cause any proteinopathy phenotype
similar to that seen in disease tissues, and was not found in
the insoluble fraction (Supplementary Fig. 1A and B).
Overexpression of wild-type or mutant TDP-43 in
HEK293 cells resulted in high levels of TDP-43 accumulat-
ing in the detergent-resistant fraction (Fig. 1B and C). This
result is consistent with previous reports showing that high
cellular levels of TDP-43 caused protein aggregation result-
ing in a decrease in protein solubility. However, co-expres-
sion of TDP-43 with HSF1( + ) led to a signiﬁcant reduction
in the level of insoluble TDP-43 to 25% (Fig. 1B and C,
P5 0.001). Conversely, HSF1() signiﬁcantly increased the
level of insoluble TDP-43 by 250% (Fig. 1B and C,
P5 0.001). The mutation status of TDP-43 when co-trans-
fected with HSF1 did not signiﬁcantly change TDP-43 pro-
tein solubility, nor did the presence of a mutation in TDP-
43 when transfected alone (Fig. 1C). HSF1( + ) showed no
obvious effect on the level of soluble TDP-43 (Fig. 1B and
D). However, soluble GFP-TDP-43 was found to slightly
decrease when co-expressed with HSF1() especially for
the cytosolic TDP-43, GFP-dNLS TDP-43 (Fig. 1B and D,
P5 0.01 for dNLS-TDP-43), suggesting the expression of
HSF1() results in an increased tendency for overexpressed
cytosolic TDP-43 to shift from soluble monomer to insol-
uble aggregates.
In summary, these results show that increased activation
of the HSR by HSF1( + ) substantially enhances the clear-
ance of insoluble TDP-43, whereas inhibition of the HSR
via HSF1() expression results in an increase in insoluble
TDP-43, likely resulting from an inhibition of the endogen-
ous, basal HSR.
HSF( + ) rescues TDP-43
hyperphosphorylation
Aside from reduced solubility, TDP-43-linked pathology is
also characterized by the presence of hyperphosphorylated
TDP-43, which can be detected by a phospho-TDP-43 spe-
ciﬁc antibody. Phospho-TDP-43 was only detectable in the
insoluble urea fraction, conﬁrming that the pathological
TDP-43 in our model is both insoluble and hyperpho-
sphorylated (Fig. 2A). The accumulation of insoluble, phos-
phorylated TDP-43 was completely inhibited in HSF1( + )
co-expressing cells (Fig. 2A and B, P5 0.01) and enhanced
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Figure 2 Expression of HSF1( + )rescues TDP-43 phosphorylation. (A) HEK293T cells co-expressing GFP-TDP-43 and V5-HSF1
constructs for 48 h followed by fractionation. Levels of phosphorylated TDP-43 from three independent transfections were quantified, normalized
to actin, and shown in relation to the GFP-wild-type TDP-43 and the vector only control. Mean and SEM are shown in (B). Two-way ANOVA
analysis indicates that the difference in TDP-43 phosphorylation is not contributed by TDP-43 genotypes or interaction between TDP-43 and
HSF1, but by HSF1 alone (P5 0.001). When co-transfected with GFP-TDP-43, both HSF1( + ) and HSF1() significantly changed the level of
phosphorylated TDP-43 compared to the vector only control (P = 0.02 and P5 0.001, respectively, Bonferroni post-test). (C–F) Phospho-TDP-
43 staining in HEK293T cells transfected for 48 h with the V5-HSF1 and GFP-TDP-43 vectors (C), GFP-WT-TDP-43 (D), GFP-M337V TDP-43 (E)
and GFP-dNLS TDP-43 (F). Scale bar = 20 mm in C. Cell counting was performed on three independent transfections, with 300 cells per
condition. Mean and SEM of frequency of GFP-TDP-43 expressing cells that are also phospho-TDP-43 stained positive (G) and GFP-TDP-43
transfection efficiency (H) are shown. (I) GFP-WT-TDP-43 and HSF1() transfected HEK293T cell stained for phospho-TDP-43 (red) and
ubiquitin (magenta). Scale bar = 5 mm.
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by HSF1() (Fig. 2A and B, P5 0.001). No phospho-TDP-
43 staining was identiﬁed in GFP-vector transfected cells
alone (Fig. 2C), indicating that TDP-43 phosphorylation
was not caused by the stress of transient transfection but
by the accumulation of aggregated TDP-43, which con-
tained endogenous TDP-43 (Supplementary Fig. 1C).
Staining for phospho-TDP-43 in cells conﬁrmed the west-
ern blot ﬁndings, with evidence of TDP-43 phosphorylation
in 10% of GFP-TDP-43 expressing cells. HSF1( + ) sub-
stantially reduced levels of TDP-43 phosphorylation in
both wild-type and mutant TDP-43 expressing cells without
altering the TDP-43 transfection efﬁciency (Fig. 2D–H). On
the other hand, HSF1() increased TDP-43 phosphoryl-
ation, which coincided with a marginal reduction in the
frequency of GFP-dNLS TDP-43 expressing cells (Fig. 2H,
P = 0.012). The genotype of the overexpressed TDP-43 had
no signiﬁcant impact on TDP-43 phosphorylation per se
(Fig. 2B and G). We also observed a slight change in
TDP-43 protein subcellular localization in this model, as
cells that co-expressed GFP-TDP-43 and HSF1( + ) tended
to have a higher proportion of nuclear TDP-43, while cells
that co-expressed GFP-TDP-43 and HSF1() displayed a
higher proportion of cytosolic TDP-43 (Supplementary
Fig. 2). In the aggravated condition where TDP-43 was
co-expressed with HSF1(), not only was phosphorylated
TDP-43 identiﬁed in both the nucleus and cytoplasm, but
30% of the cytosolic phosphorylated TDP-43 inclusions
were also ubiquitin-positive (Fig. 2I).
To further validate these ﬁndings in a neuronal model,
we overexpressed GFP-TDP-43 with HSF1 in rat primary
cortical neurons (Fig. 3). Overexpression of GFP vector did
not induce TDP-43 phosphorylation in transfected neurons
(Fig. 3B), which again demonstrates that exogenous protein
expression is not the cause of TDP-43 hyperphosphoryla-
tion. When primary neurons were transfected with GFP-
TDP-43 alone, expression was largely conﬁned to nuclei
(65.9  1.48%) but cytoplasmic localization of phosphory-
lated TDP-43 was also observed in a signiﬁcant minority of
cells (31.2  0.54%) (Fig. 3C, top). In HSF1( + )/GFP-TDP-
43 expressing cells, all TDP-43 displayed a nuclear local-
ization with no evidence of phosphorylation (Fig. 3C,
middle). However, in cells co-expressing HSF1() and
GFP-TDP-43, there was a dramatic reduction of nuclear
TDP-43 and accumulation of hyperphosphorylated TDP-
43 in the cytoplasm (Fig. 3C, bottom). The clearance of
nuclear TDP-43 in cells containing large cytoplasmic aggre-
gates is in agreement with observations of pathological
TDP-43 in ALS patient tissues (Neumann et al., 2006).
Of note, GFP-positive cells co-expressing HSF1() were
very rare, and many had lost their neuron-like morphology
Figure 3 Effect of HSF1 on TDP-43 cellular distribution and phosphorylation in primary neurons. (A) Rat primary cortical neurons
were transfected with GFP-WT-TDP-43 (green) and V5-HSF1 (red). bIII-tubulin (magenta) is used as a neuronal marker. (B and C) GFP vector (B)
or GFP-wild-type TDP-43 with V5-HSF1 (C) are transfected into the rat primary cortical neurons. Cells were fixed 6 days after transfection and
stained for V5 (magenta), phospho-TDP-43 (red) and nuclei (DAPI, blue). Scale bar = 10 mm.
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(Fig. 3A and C), suggesting that TDP-43 cytotoxicity is
enhanced when the HSR is suppressed.
Our cellular model of TDP-43 proteinopathy replicates
several features of human disease with the accumulation
of insoluble phosphorylated and ubiquitinated TDP-43 in
the cytoplasm. We have also shown that the activation of
the HSR rescues TDP-43 pathology whereas blocking this
response exacerbates TDP-43 accumulation.
HSF1( + ) rescues TDP-43-induced
cell death
As reported in other cellular and transgenic animal studies,
overexpression of TDP-43 can be cytotoxic to some cells,
especially neurons (Ash et al., 2010; Barmada et al., 2010;
Stallings et al., 2010; Wils et al., 2010). When either wild-
type or ALS-associated mutant TDP-43 were overexpressed
in the SH-SY5Y neuronal cell line, a signiﬁcant reduction in
cell survival was observed from those GFP-TDP-43 express-
ing cells (Fig. 4A and B and Supplementary Fig. 3), indicat-
ing that the overexpression of TDP-43 is indeed toxic to
neuronal cells. This cytotoxicity can, however, be partially,
but signiﬁcantly rescued, by the presence of HSF1( + ) (Fig.
4C and D). Similar ﬁndings were obtained in cells over-
expressing ALS-linked mutant TDP-43. Conversely, al-
though overexpression of GFP-dNLS TDP-43 resulted in
similar levels of cell death as the other GFP-TDP-43 con-
structs, expression of HSF1( + ) was only able to induce a
Figure 4 Expression of HSF1( + ) rescues TDP-43 toxicity. (A) Cell death analysis performed on SH-SY5Y transfected with GFP-TDP-43
for 48 h. GFP-positive cells are plotted in this figure where dying cells are shown with reduced fluorescent intensity for calcine AM (as gated). GFP
vector-expressing cells are indicated in shaded line whereas coloured lines represent the different genotypes of GFP-TDP-43 expressing cells. (B)
Amount of dying GFP positive cells averaged from three independent transfections with SEMs displayed. Both wild-type and mutant TDP-43 are
found to cause significant cell death compared to GFP vector control (one-way ANOVA followed by Bonferroni post-test, P5 0.001). (C) One
representative experiment showing that the presence of HSF1( + ) (blue line) reduces the level of dying GFP-TDP-43 expressing cells (red line).
Average cell death from three transfections are shown in (D). T-test was used to determine whether HSF1( + ) significantly rescues TDP-43
induced cell death. P5 0.05; P5 0.01; P5 0.001.
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non-signiﬁcant (P = 0.246) reduction in cell death.
Overexpression of TDP-43 in HEK293 cells did not show
cytotoxicity (data not shown), supporting the observation
in ALS studies that neuronal cells are particularly sensitive
to TDP-43 cytotoxicity.
In summary, we have demonstrated that overexpressing
TDP-43 in cells recapitulates pathological features of the
TDP-43 proteinopathies and that the presence of these fea-
tures results in an increase in cell death. Manipulating the
heat shock response (HSR) by expression of HSF1( + ) re-
duces this pathological TDP-43, and improves cell survival.
In contrast, when cells are deprived of their basal heat
shock response activity by the expression of HSF1(), the
degree of TDP-43 proteinopathy is intensiﬁed.
DNAJB2a as a potential mediator of
HSF1-induced TDP-43 aggregation
suppression
HSF1 is a transcription factor that is responsible for the
induction of a wide range of HSPs and other stress-respon-
sive proteins upon its activation (Velichko et al., 2013;
Vihervaara et al., 2013). As overexpression of HSF1( + )
increased endogenous levels of HSP40 and HSP70, this
indicated that HSF1( + ) was triggering the heat shock re-
sponse as expected (Fig. 1B). To determine which chaper-
one proteins may participate in TDP-43 clearance, we
screened a selection of HSPs, including HSP90, HSP70,
Hsc70, HSP27 and most of the HSP40s from the DNAJA
and DNAJB families that were previously screened for their
ability to suppress polyQ aggregation (Hageman et al.,
2010). Most of the HSPs tested displayed little or no
effect on TDP-43 solubility, however, two HSP40s,
DNAJB2a and DNAJB8a, resulted in a reduction of insol-
uble TDP-43 similar to that observed with HSF1( + )
(Fig. 5). As DNAJB8a has a very restricted expression pat-
tern and can only be found in testis tissue, we did not test
this further. DNAJB2a displays a neuronal enriched expres-
sion proﬁle (Cheetham et al., 1992; Chapple and
Cheetham, 2003; Hageman and Kampinga, 2009), and
was chosen for further investigation.
DNAJB2a maintains the solubility of
TDP-43 by interacting with HSP70
DNAJB2a, encoded by DNAJB2 and also known as
HSJ1a, is a target of HSF1 (Vihervaara et al., 2013) and
functions as a co-chaperone for HSP70 interacting through
its J domain (Fig. 6A; Cheetham et al., 1994). In addition
to working with HSP70, DNAJB2a also binds client pro-
teins independently and can target them to the proteasome
for degradation through its ubiquitin interacting motif
(UIM) (Fig. 6A; Westhoff et al., 2005). To investigate the
nature of this HSF1-DNAJB2a-mediated TDP-43 aggrega-
tion clearance, we expressed GFP-wild-type TDP-43 with
either wild-type or selected mutants of DNAJB2a. The
H31Q mutation in DNAJB2a disrupts the interaction be-
tween DNAJB2a and HSP70, thereby impeding the co-
chaperone activity of DNAJB2a. The DNAJB2a-dUIM
bears four point mutations in the UIM, which prevent
DNAJB2a from delivering client proteins to the proteasome
for degradation (Westhoff et al., 2005). Interestingly, the
DNAJB2a-mediated reduction in insoluble/phosphorylated
TDP-43 was not altered by the presence of the dUIM mu-
tations, whereas the presence of the H31Q mutation com-
pletely disrupted this activity (Fig. 6B). These ﬁndings
suggest that DNAJB2a reduces the level of insoluble TDP-
43 by co-operating with HSP70 to enhance refolding and
maintain solubility, rather than by causing the degradation
of the insoluble protein. In support of this hypothesis, treat-
ment of GFP-WT-TDP-43 expressing cells with the prote-
asome inhibitor, MG-132, which led to the build-up of
insoluble TDP-43 (Fig. 6C), had minimal impact on
HSF1( + )/DNAJB2a-mediated TDP-43 aggregation suppres-
sion (Fig. 6C). Both the DNAJB2a functional mutations
study and the study of ubiquitin proteasome system inhib-
ition by MG-132 suggest that protein degradation does not
play a major role in HSF1-DNAJB2a-mediated TDP-43 ag-
gregation clearance. This is further supported by our ob-
servation that autophagy inhibition by baﬁlomycin
treatment showed minimal effect on HSF1( + )/DNAJB2a-
mediated TDP-43 aggregation clearance (Supplementary
Fig. 4).
An immunopuriﬁcation study provided further evidence
to support the existence of a DNAJB2a-HSP70-TDP-43 re-
folding complex, since TDP-43 was shown to interact with
both DNAJB2a and HSP70 (Fig. 6D and E). Although the
co-chaperone’s binding to the client protein is in general
transient and dynamic, we were able to detect TDP-43
binding to all three forms of DNAJB2a. The binding to
H31Q-DNAJB2a was stronger than the others, probably
due to its inability to transfer the client protein to
HSP70, therefore prolonging binding (Fig. 6D).
These results show that the HSF1-induced co-chaperone,
DNAJB2a, reduced levels of insoluble TDP-43 not through
degrading these aggregated, phosphorylated proteins, but
by directing them to HSP70 to be refolded (Fig. 6 and
Supplementary Fig. 5). As TDP-43 is tightly controlled to
maintain its cellular level, and is known to be aggregation-
prone especially under stress, our ﬁnding suggests a promis-
ing therapeutic strategy which uses the heat shock response
mechanism to regain the neutral TDP-43 protein
homeostasis.
HSF1/heat shock proteins are
reduced in ALS mouse model and
affected patient tissues
The HSR is a powerful mechanism to cope with cellular
stress, which we show in this study can efﬁciently refold
insoluble TDP-43 and dissolve features of TDP-43 protei-
nopathy; however, it has been shown to be compromised in
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Figure 5 Screening for HSPs that mediate HSF1( + )-induced TDP-43 clearance. (A) HEK293T cells co-express GFP-TDP-43 and V5-
HSP constructs for 48 h followed by fractionation. Levels of insoluble TDP-43 from three independent transfections are quantified, normalized to
actin and shown in relative to control. Mean and SEM are shown in (B).
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some neurodegenerative conditions (Hay et al., 2004;
Maheshwari et al., 2014). To characterize further the in-
volvement of HSF1/HSPs in TDP-43 proteinopathy in ALS,
levels of HSF1 and HSPs proteins were investigated in ALS
mouse model and patient tissues.
To study the role of TDP-43 in the development and
progression of ALS, lines of transgenic mice expressing
either wild-type-TDP-43, Q331K-TDP-43 or both were es-
tablished (Mitchell et al., 2015). A correlation between the
level of TDP-43 protein and phenotypic severity was noted,
with the strain that expressed the highest level of TDP-43
(TDP-43WTxQ331K double transgene) suffering from the
most severe motor deﬁcits and TDP-43 pathology, and a
drastically reduced life span compared to both single and
non-transgenic mice (Mitchell et al., 2015).
Interestingly, HSF1 was decreased in the TDP-43Q331K
single transgenic mice that displayed a mild, non-lethal
motor defect at later stage (Fig. 7A and Mitchell et al.,
2015), but was most signiﬁcantly lost in diseased TDP-
43WTxQ331K mice (Fig. 7A). As a result of the loss of
HSF1, levels of HSP70 and HSP40 were also decreased
substantially in TDP-43WTxQ331K mice, whereas HSP90 re-
mained unaffected. Immunohistochemical staining also
showed reduced levels of HSF1 in the remaining motor
neurons in the end-stage diseased mice spinal cord sections,
(Fig. 7B) indicating that the reduction in HSF1 protein was
not purely a result of motor neuron loss.
Examination of HSF1 and the HSPs in human tissue
identiﬁed a signiﬁcant decrease in HSP70 (Fig. 7D) and
HSP40 (Fig. 7E) despite no signiﬁcant change in HSF1
levels between sporadic ALS and control tissues (Fig. 7C).
It is known that total level of HSF1 is not always correlated
with its level of activity, instead, certain post-translational
modiﬁcations are required to activate the protein
(Westerheide et al., 2009; Calderwood et al., 2010; Yih
et al., 2012). This regulation in HSF1 activity is likely to
be responsible for the difference we see in affected tissues in
ALS, where HSP40 and 70 are reduced, despite no appar-
ent change in the total levels of HSF1. We therefore pro-
pose that a reduction in HSF1 activity results in a reduction
in HSPs, which in turn contributes to the enhanced accu-
mulation and aggregation of TDP-43 in ALS patients.
Figure 6 DNAJB2a mediates TDP-43 refolding through
introducing TDP-43 to HSP70. (A) Domain structure of
DNAJB2a, showing the position of the J (and H31), client binding
(CBD) and UIM domains. (B) HEK293T cells co-expressing GFP-
Figure 6 Continued
wild-type TDP-43 and myc-DNAJB2a constructs for 48 h followed
by fractionation. Levels of insoluble TDP-43 are shown with GFP
antibody and phospho-TDP-43 is detected by a phospho-TDP-43
specific antibody. (C) Cells co-expressing GFP-WT-TDP-43 and
vector only (vec), HSF1( + ), or myc-DNAJB2a were treated with
the ubiquitin proteasome system inhibitor, MG-132 (0.5 mM, 40 h)
followed by fractionation. (D) Co-immunopurification of GFP-TDP-
43 and myc-DNAJB2a. Myc-DNAJB2a is pulled down by the myc
antibody and GFP-TDP-43 is detected with TDP-43 antibody. (E)
Co-immounopurification of GFP-TDP-43 and V5-HSFP70. V5-
HSP70 and V5-HSP90 are pulled down by V5 antibody and GFP-
TDP-43 is detected with the GFP antibody.
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Taken together, our results suggest that the HSR is com-
promised in both the TDP-43 transgenic ALS mouse model
and in patient tissues, which could be initiated either dir-
ectly or indirectly by long term TDP-43 protein overexpres-
sion. Additionally, these results demonstrate that a
reduction in the HSR leads to decreased TDP-43 refolding
efﬁciency, promoting the accumulation of phosphorylated
insoluble TDP-43.
Discussion
In this study, we generated a cellular model of the human
TDP-43 proteinopathies that developed detergent-resistant,
hyperphosphorylated cytoplasmic insoluble TDP-43 aggre-
gates that are cytotoxic. Co-expression of a dominant posi-
tive version of the master regulator of the heat shock
response HSF1 induced a dramatic clearance of insoluble
TDP-43 aggregates without affecting the levels of soluble
TDP-43. Conversely the dominant negative version of
HSF1 lead to a massive accumulation of insoluble and
hyperphosphorylated TDP-43 aggregates conﬁrming a
vital role of the HSF1-HSP axis in physiological TDP-43
proteostasis. We have shown that HSF1-induced TDP-43
clearance is partly mediated by HSP70 and its co-chaper-
one DNAJB2a in a proteasome- and autophagy-independ-
ent manner. We propose that DNAJB2a recognizes and
binds to insoluble TDP-43 taking it to the chaperone pro-
tein HSP70, which then refolds the protein. Once it has
been returned to its soluble, properly folded status, TDP-
43 is then released to perform its biological functions
(Fig. 8). Because DNAJB2a mediates TDP-43 refolding
without involving the proteasome or autophagy, it is able
to reduce TDP-43 toxicity without changing the levels of
soluble TDP-43.
We have also shown that levels of several HSR proteins
are reduced in transgenic mice and sporadic ALS tissues
implying that the HSF1–HSP axis may be compromised
due to the disease process. Q331K TDP-43 transgenic
mice develop a slowly progressive motor phenotype and
have moderately reduced levels of HSF1 and HSP-40,
whereas the severely-affected double transgenic mice have
Figure 7 The HSR is downregulated in the affected tissues of both TDP-43 mouse model and sporadic ALS. (A) Whole spinal
cord lysates are prepared from 8-week-old non-transgenic (Ntg), wild-type TDP-43 single transgenic (WT), Q331K-TDP-43 single transgenic (Q)
and WTxQ331K-TDP-43 double transgenic (WTxQ) mice. Endogenous and transgenic TDP-43 protein levels are shown with TDP-43 blotting;
components of the HSR are shown with HSF1, HSP70, HSP40 and HSP90; neuronal markers, bIII tubulin and ChAT, are also shown for indication
of neuronal loss. Actin is used as a loading control. (B) Immunohistochemistry staining for HSF1 in spinal cord sections of non-transgenic and
double transgenic animals at 8 weeks old. Selective motor neurons indicated by arrows, and inset. Scale bar = 50 mm. Levels of HSF1 (C), HSP70
(D), and HSP40 (E) of control and sporadic ALS spinal cord lysate are shown. 15 control and 15 sporadic ALS (SALS) samples were used in this
study, representative western blots are shown with all samples plotted for t-test comparison. P5 0.05; P5 0.01.
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a dramatic loss of HSF1, HSP40 and HSP70. In human
spinal cord tissues the levels of HSP70 and HSP40 were
signiﬁcantly reduced but not HSF1.
The data from our cellular, animal and human tissue
studies indicate that the HSF1/HSP70/DNAJB2a pathway
plays a vital role in the physiological maintenance of TDP-
43 proteostasis. In the disease state, however, the HSR ap-
pears to be compromised and may contribute to the accu-
mulation of insoluble TDP-43 protein aggregates and
exacerbate defective proteostasis (Fig. 8).
Involvement of heat shock proteins in
neurodegenerative disorders
Molecular chaperones are essential for maintaining proteos-
tasis (Smith et al., 2015). Neurodegenerative disorders are
characterized by the presence of aggregated aberrant pro-
teins in affected neural tissues, so the role of HSR proteins
and the opportunities for therapy is of great interest.
Reduced levels of HSR components are found in affected
neuronal tissues from patients with Huntington’s disease
(Maheshwari et al., 2014) and ALS (Anagnostou et al.,
2010) and a failed stress response has been implicated in
ageing and neurodegenerative disorders (Brehme et al.,
2014). Overexpression of individual HSPs in cellular and
transgenic animal models of disease have shown variable
degrees of success. In some cases, overexpression of a single
HSP was sufﬁcient to reduce protein aggregation and im-
prove survival, such as: HSP70 for -synuclein (Auluck
et al., 2002; Dedmon et al., 2005), DNAJB6b and
DNAJB8 for poly-Q (Hageman et al., 2010), HSP27 for
tau and SOD1 (Shimura et al., 2004; Sharp et al., 2008)
and HSPB8 for SOD1 (Crippa et al., 2010). In other cases,
both HSP70 and HSP40 were required to clear aberrant
protein aggregates (Krobitsch and Lindquist, 2000; Lotz
et al., 2010). The differences are likely to be due to sub-
strate speciﬁcity and the particular model used in the study.
The HEK293T cells used in our study have high levels of
HSP70 in basal conditions but relatively low levels of
HSP40 (Fig. 1B). As the level of HSP40 was a limiting
factor in our cellular model, it may explain why we
observed no rescue of TDP-43 pathology in response to
HSP70 overexpression alone (Fig. 5A), despite evidence
that the interaction between HSP70 and DNAJB2a is es-
sential for insoluble TDP-43 clearance (Fig. 6B). Unlike
HSP70, DNAJB2a expression is speciﬁcally enriched in
neuronal tissues (Chapple and Cheetham, 2003; Hageman
and Kampinga, 2009) and mutations in DNAJB2 are linked
to a rare recessive distal hereditary motor neuropathy and
Charcot–Marie–Tooth disease type 2 (Blumen et al., 2012;
Gess et al., 2014) implying a critical need for this co-chap-
erone. Overexpression of DNAJB2a was protective in
G93A-SOD1 mouse model of ALS (Novoselov et al.,
2013) and mutant huntingtin in R6/2 transgenic mice
(Labbadia et al., 2012). These results, in combination
with our own data on TDP-43, provide convincing evi-
dence that DNAJB2a plays an important role in neuronal
survival and the capacity of neurons to cope with aberrant
Figure 8 Proposed model of HSR involvement in TDP-43 protein refolding and proteinopathy. In the healthy condition with a
functional HSR, HSF1 activates the expression of HSPs such as HSP70 and DNAJB2a. DNAJB2a recognizes misfolded TDP-43 in the cytosol and
brings it to the chaperone protein, HSP70. HSP70 catalyzes the refolding of TDP-43, returns it to its native soluble state, which enables TDP-43 to
shuttle back to the nucleus. In the diseased condition, the HSR is impaired by either reduced protein levels or the decreased activity of HSF1. In
either condition, this leads to a reduction of HSPs, which subsequently fail to efficiently engage misfolded TDP-43. As a result, the insoluble and
phosphorylated TDP-43 proteins accumulate and form cytosolic aggregates in disease affected cells.
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protein aggregation. Interestingly, both the refolding (J) and
proteasome (UIM) domains of DNAJB2a were required for
mutant SOD1 and huntingtin protein clearance, whereas
we demonstrated that TDP-43 clearance was achieved by
HSP70/DNAJB2a-mediated refolding and not proteasome
clearance. The marked reduction in TDP-43 C-terminal
phosphorylation indicates that the protein is in a near
native and probably functional state. A similar result was
seen where DNAJB2a suppressed the aggregation of mutant
parkin and enhanced mitophagy in a J domain-dependent
and UIM-independent manner (Rose et al., 2011). This
result demonstrates that the diverse function of DNAJB2a
to mediate protein clearance either through refolding or
degradation depends on the nature and the structure of
the protein client.
Interactions between HSPs and TDP-43 have been docu-
mented previously. Freibaum et al. (2010) conducted a
proteomic screening which identiﬁed a group of HSPs inter-
acting with TDP-43, including HSP70 and HSP40. These
ﬁndings were later validated in cellular model (Chang et al.,
2013; Udan-Johns et al., 2014). Both studies suggested that
the HSP-TDP-43 interaction plays a role in stress-induced
TDP-43 aggregation. However, as the HSP expression pat-
tern is cell type speciﬁc, the exact role of the HSP-TDP-43
interaction in the context of neurodegeneration is still yet
fully explored.
Cellular stress and TDP-43 aggrega-
tion: is heat shock response activation
enough to help?
TDP-43 is an aggregation-prone protein that is found to
form detergent-resistant aggregates or stress granules
during conditions of cellular stress such as heat shock
(Supplementary Fig. 6; Udan-Johns et al., 2014), osmotic,
and oxidative stress (Dewey et al., 2011; McDonald et al.,
2011; Chang et al., 2013). Studies in cellular models show
that despite TDP-43 aggregates forming quickly in response
to stress, those aggregates can be readily disassembled
when the stress is removed (Supplementary Fig. 6; Scotter
et al., 2014). Several cellular mechanisms have evolved to
participate in resolving potentially detrimental protein ag-
gregates. The ubiquitin proteasome system has been found
to be responsible for the majority of TDP-43 protein deg-
radation, whereas the autophagy pathway is required to
clear larger aggregates (Scotter et al., 2014). Indeed, we
observed an increase in TDP-43 aggregation when the pro-
teasome was inhibited by MG132 (Fig. 6B); however, nei-
ther proteasome nor autophagy inhibition reduced the
effectiveness of HSF1 or DNAJB2a overexpression, further
conﬁrming that they do not appear to be targeting TDP-43
for degradation. Upstream of these pathways, the chaper-
one system facilitates protein folding and directs the deg-
radation of misfolded proteins. However, due to their
highly speciﬁed structures, neurons have higher demand
for these chaperone and protein degradation systems to
maintain protein homeostasis, which appear to fail in
ageing and disease (Brehme et al., 2014). In addition,
motor neurons have a higher threshold for the activation
of the HSR than most other cells (Batulan et al., 2003).
Thus there may be a delay in the activation of the chaper-
one system in response to stress, creating a cascade where
the protein quality and degradation systems begin to fail
and aberrant protein aggregates form. If and when, the
HSR eventually does come into play, it may be too little
too late. Indeed, there is no evidence to date to suggest that
the HSR is activated in diseased tissues and may actually be
inhibited (Fig. 7) (Anagnostou et al., 2010; Maheshwari et
al., 2014). Our data suggest that the enforced activation of
the HSR, in particular the neuronal speciﬁc co-chaperone,
DNAJB2a, could effectively rescue TDP-43 proteinopathy
by restoring aggregated TDP-43 to its native state.
HSP90 binds to and inactivates HSF1 by preventing it
from entering the nucleus and inducing the HSR. HSP90
inhibitors such as 17-AAG have therefore been tested in
cellular and animal models of neurodegeneration with
some success (Waza et al., 2005; Fujikake et al., 2008;
Rusmini et al., 2011; Gregory et al., 2012). However, as
HSP90 is involved in cell cycle and cell survival pathways
(Taipale et al., 2010), the risk of toxic side effects of
HSP90 inhibitors limit their attractiveness as a potential
therapy. We have shown that activation of HSF1/HSP70/
DNAJB2a pathway results in a dramatic clearance of TDP-
43 aggregates and that directly targeting these HSR com-
ponents is an important therapeutic opportunity for ALS.
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